ATLANTA, GA - June 10, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies against infectious diseases ...

The 36-month PFS rate for patients with del (17p) and/or TP53 mutation was 87% and for patients without del (17p) and TP53 mutation was 89%. The safety profile of BRUKINSA plus venetoclax was ...

Management Considerations for Patients With Primary Refractory and Early Relapsed Diffuse Large B-Cell Lymphoma While the past decade has witnessed unprecedented progress for patients with chronic ...

Jaypirca demonstrated superior overall response rates and progression-free survival trends compared to Imbruvica in the BRUIN CLL-314 trial for CLL/SLL patients. The trial is the first head-to-head ...

Good evening, everyone. My name is Arthur Sands. I'm President and CEO of Nurix Therapeutics. And I'd like to welcome you to our 2025 Investor and Analyst event broadcasting here from Orlando, Florida ...

Chronic lymphocytic leukemia (CLL) and prolymphocytic leukemia (PLL) are types of blood cancer. They develop in types of white blood cells called B cells or T cells, or the precursors to these cells.

Ten of 13 patients with leukemic pulmonary infiltrates (LPI) and chronic lymphocytic leukemia (CLL) had single or multiple nodular/mass-like opacities, authors found. The study authors explained that ...

NORTH CHICAGO, Ill., Dec. 10, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new and updated data across clinical and real-world studies in chronic lymphocytic leukemia (CLL). Presentations ...

Chronic lymphocytic leukemia (CLL) is the most common leukemia among adults in the western world, presenting at a median age of 65 years. 1 The diagnosis is often made incidentally during routine ...